Vir Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vir Biotechnology, Inc. on December 10, 2020, reporting events that occurred on December 9, 2020. The Company is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Select Market under the symbol "VIR."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from 10 to 11 members.
- New Appointment: Mr. Jeffrey Hatfield was appointed as a Class III director effective December 9, 2020, serving until the 2022 annual meeting of stockholders.
- Committee Assignment: Mr. Hatfield was appointed to the Audit Committee effective immediately upon his Board appointment.
Compensation and Equity Grant
In connection with his appointment, Mr. Hatfield received compensation in accordance with the Company's non-employee director policy:
- Stock Option Grant: An option to purchase 46,500 shares of common stock under the 2019 Equity Incentive Plan.
- Exercise Price: $29.43 per share (closing price on December 9, 2020).
- Vesting Schedule: One-third vests on the one-year anniversary of appointment; the remainder vests monthly over the subsequent two years, contingent on continued service.
- Term: 10 years.
- Indemnification: The Company entered into a standard indemnification agreement with Mr. Hatfield.
Outlook, Risks, and Contingencies
The filing text does not provide a clear value for guidance, outlook, management commentary on business risks, or contingencies. The document contains no unusual items or forward-looking financial statements.
Key Facts for Investor Verification
- Verify the total number of outstanding shares and the dilution impact of the 46,500 share option grant.
- Confirm Mr. Hatfield's qualifications and independence status as a new Audit Committee member.
- Review the Company's 2019 Equity Incentive Plan terms regarding change of control acceleration.
- Check the Company's cash position to ensure it can meet future director compensation obligations.